Antiplatelet therapy following myocardial infarction in patients with diabetes

JAMA

Volumn 308, Issue 9, 2012, Pages 921-922

  Bhatt, Deepak L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; BODY MASS; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CORONARY STENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK REDUCTION; SECONDARY PREVENTION; THERAPY EFFECT; TREATMENT RESPONSE; CARDIOVASCULAR DISEASE; FEMALE; MALE; MORTALITY; NOTE;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84865694063     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/2012.jama.11467     Document Type: Editorial

References (18)

1. Bhatt DL, Eagle KA, Ohman EM, et al REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304(12):1350-1357.
2. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000;35(4):922-928. (Pubitemid 30189923)
3. Andersson C, Lyngbæk S, Nguyen CD, et al. Association of clopidogrel treatment with risk of mortality and cardiovascular events following myocardial infarction in patients with and without diabetes. JAMA. 2012;308(9):882-889.
4. Chen ZM, Jiang LX, Chen YP, et al; COMMIT collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction. Lancet. 2005;366(9497):1607-1621.
5. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502. (Pubitemid 32758501)
6. Kolandaivelu K, Bhatt DL. Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nat Rev Cardiol. 2010;7(8):461-467.
7. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16):1541-1547. (Pubitemid 47532327)
8. Wiviott SD, Braunwald E, McCabe CH, et al TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)
9. Wallentin L, Becker RC, Budaj A, et al PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
10. Hamm CW, Bassand JP, Agewall S, et al ESC Committee for Practice Guidelines; Document Reviewers. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2011;32(23):2999-3054.
11. Jneid H, Anderson JL, Wright RS, et al; 2012 Writing Committee Members. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update). Circulation. 2012;126(7):875-910.
12. Wiviott SD, Braunwald E, Angiolillo DJ, et al TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626-1636.
13. James S, Angiolillo DJ, Cornel JH, et al PLATO Study Group. Ticagrelor vs clopidogrel in patients with acute coronary syndromes and diabetes. Eur Heart J. 2010;31(24):3006-3016.
14. Bhatt DL, Fox KA, Hacke W, et al CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-1717.
15. Bhatt DL, Flather MD, Hacke W, et al CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982-1988. (Pubitemid 46694290)
16. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.
17. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90(6):625-628. (Pubitemid 35264538)
18. Pulcinelli FM, Biasucci LM, Riondino S, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30(10):1279-1286.